Prevalence of symptoms experienced by patients with different clinical types of psoriasis

The British Journal of Dermatology
F SampognaIDI Multipurpose Psoriasis Research on Vital Experiences Investigators

Abstract

The main dermatology textbooks describe only in passing pruritus in psoriasis and rarely mention other symptoms. A quantification of the presence of symptoms is not available for clinical subgroups of psoriasis. To investigate the prevalence of symptoms experienced by patients with different clinical types of psoriasis. The study was carried out in patients hospitalized for psoriasis between February 2000 and February 2002 at the inpatient wards of the Istituto Dermopatico dell'Immacolata, Rome, Italy. Symptoms were evaluated using the symptoms scale of Skindex-29. Clinical severity was assessed by the dermatologists using the Psoriasis Area and Severity Index (PASI), and by the patients completing the self-administered PASI. Psychiatric morbidity was evaluated using the 12-item General Health Questionnaire. In total, 936 eligible patients were analysed. The proportions of patients experiencing symptoms often or always in the 4 weeks before hospitalization were: 63.8% itching, 59.7% irritation, 46.1% burning/stinging, 39% sensitivity, 26% pain (from 10% in guttate psoriasis to 50% in arthropathic), 25.4% bleeding (17% pustular, 19% localized plaque, 36% palmoplantar), and 23.9% bothered by water (from 8.5% in the guttate form t...Continue Reading

References

Jan 1, 1978·Dermatologica·T Fredriksson, U Pettersson
Jan 1, 1987·Social Psychiatry. Sozialpsychiatrie. Psychiatrie Sociale·C BellantuonoM Tansella
Feb 1, 1995·The British Journal of Dermatology·A Y Finlay, E C Coles
Jan 1, 1996·The Journal of Investigative Dermatology·S R FeldmanL Nurre
Mar 1, 1997·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·L W LawrenceA Davidson
Nov 20, 1998·Journal of the American College of Cardiology·P H SpoonerG D Pennock
Aug 19, 2000·Psychosomatic Medicine·D SheffieldD S Sheps
Nov 9, 2000·The British Journal of Dermatology·G YosipovitchC L Goh
Jan 5, 2002·Journal of the European Academy of Dermatology and Venereology : JEADV·A PicardiP Pasquini
Feb 9, 2002·Dermatology : International Journal for Clinical and Investigative Dermatology·Damiano AbeniMary Margaret Chren
Mar 8, 2003·Archives of Dermatology·Francesca SampognaUNKNOWN IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Study Group
Aug 23, 2003·The British Journal of Dermatology·E MazzottiUNKNOWN IDI Multipurpose Psoriasis Research on Vital Experiences study group
Nov 18, 2003·The British Journal of Dermatology·M NakamuraM Morohashi
Apr 17, 2004·The Journal of Investigative Dermatology·Francesca SampognaUNKNOWN IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Investigators

❮ Previous
Next ❯

Citations

Jun 1, 2012·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·E Weisshaar
Jan 27, 2012·Clinical Reviews in Allergy & Immunology·Mary Ann N Johnson, April W Armstrong
Oct 4, 2007·Dermatology : International Journal for Clinical and Investigative Dermatology·F SampognaUNKNOWN Italian Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) study group
Jan 25, 2008·Dermatology : International Journal for Clinical and Investigative Dermatology·Amaro García-DiezGuillermo Sellers Fernández
Nov 3, 2006·International Journal of Behavioral Medicine·Lisette VerhoevenAndrea Evers
Jan 1, 2009·Clinical, Cosmetic and Investigational Dermatology·F PrignanoT Lotti
Apr 18, 2015·The Journal of Dermatological Treatment·Neil J KormanMary Helen Tran
Mar 31, 2015·The Journal of Dermatological Treatment·Mona L MartinHema N Viswanathan
Feb 19, 2016·Clinical and Experimental Dermatology·J F MerolaA A Qureshi
Aug 12, 2009·Current Medical Research and Opinion·Andrew P YuParvez M Mulani
Jul 6, 2010·Journal of the American Academy of Dermatology·Alice GottliebDenise Globe
Dec 1, 2009·Journal of the American Academy of Dermatology·Smitha GowdaSteven R Feldman
May 13, 2005·The British Journal of Dermatology·A Y Finlay
Apr 22, 2008·Journal of the European Academy of Dermatology and Venereology : JEADV·B AmatyaK Nordlind
Apr 26, 2006·The British Journal of Dermatology·F SampognaUNKNOWN IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) investigators
Aug 23, 2006·Journal of the European Academy of Dermatology and Venereology : JEADV·W-H BoehnckeUNKNOWN European Dermatology Expert Group
Nov 1, 2006·The Journal of Dermatology·Aylin Türel ErmertcanSerap Oztürkcan
Jan 26, 2006·The British Journal of Dermatology·F SampognaUNKNOWN Italian Multipurpose Psoriasis Research on Vital Experiences (Improve) Study Group
May 31, 2007·The British Journal of Dermatology·E W M VerhoevenA W M Evers
May 31, 2007·The British Journal of Dermatology·S-E ChangJ-H Choi
Jan 4, 2012·The Journal of Dermatology·Hyuck Hoon KwonJai Il Youn
Mar 10, 2011·Journal of the European Academy of Dermatology and Venereology : JEADV·T M LjosaaA K Wahl
Dec 21, 2011·International Journal of Dermatology·Hyuck Hoon KwonJai Il Youn
Sep 24, 2010·The Journal of Dermatology·Hyun-Chang KoKyung-Sool Kwon
Feb 9, 2011·The British Journal of Dermatology·B AmatyaK Nordlind
Oct 1, 2014·International Journal of Dermatology·Rosa María Fernández-TorresEduardo Fonseca
Nov 23, 2013·International Journal of Dermatology·Konrad JanowskiJarosław Bogaczewicz
Dec 18, 2014·International Journal of Dermatology·April N NaegeliEmily Edson-Heredia
Nov 8, 2014·Journal of the European Academy of Dermatology and Venereology : JEADV·U MrowietzR L Boggs
Feb 14, 2015·The British Journal of Dermatology·H KitchenC Bundy
Aug 22, 2013·Journal of the European Academy of Dermatology and Venereology : JEADV·F AyalaC Potenza
Jul 31, 2013·Neuroscience·Tasuku Akiyama, E Carstens
Dec 12, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Paul SwinburnBas Janssen
Mar 17, 2010·Pain·Antoinette I M van LaarhovenAndrea W M Evers
Apr 20, 2010·Actas dermo-sifiliográficas·C Porto FerreiraA M Da-Cruz
Jul 5, 2016·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·A Tsianakas, U Mrowietz
Feb 9, 2016·The British Journal of Dermatology·A B KimballG Yosipovitch
Dec 26, 2009·Journal of Autoimmunity·Vinod Chandran, Siba P Raychaudhuri
Jul 28, 2016·American Journal of Clinical Dermatology·Carolyn StullGil Yosipovitch
Nov 11, 2014·Dermatitis : Contact, Atopic, Occupational, Drug·Alexandra Price, David E Cohen
Jun 9, 2012·Dermatology : International Journal for Clinical and Investigative Dermatology·K A P MeeuwisM M van Rossum
Sep 30, 2015·European Journal of Pain : EJP·J C Szepietowski, A Reich

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The British Journal of Dermatology
Jacek C SzepietowskiB Wisnicka
Journal of the European Academy of Dermatology and Venereology : JEADV
B AmatyaK Nordlind
© 2021 Meta ULC. All rights reserved